HUE026005T2 - Treatment of brain metastases with a combination of endothelin receptor inhibitors and cytotoxic chemotherapeutic agents - Google Patents

Treatment of brain metastases with a combination of endothelin receptor inhibitors and cytotoxic chemotherapeutic agents Download PDF

Info

Publication number
HUE026005T2
HUE026005T2 HUE10742690A HUE10742690A HUE026005T2 HU E026005 T2 HUE026005 T2 HU E026005T2 HU E10742690 A HUE10742690 A HU E10742690A HU E10742690 A HUE10742690 A HU E10742690A HU E026005 T2 HUE026005 T2 HU E026005T2
Authority
HU
Hungary
Prior art keywords
cells
paclitaxel
astrocytes
brain
cell
Prior art date
Application number
HUE10742690A
Other languages
English (en)
Hungarian (hu)
Inventor
Isaiah J Fidler
Sun-Jin Kim
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE026005(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of HUE026005T2 publication Critical patent/HUE026005T2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077Beam delivery systems
    • A61N5/1084Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0622Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/08Coculture with; Conditioned medium produced by cells of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/30Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
HUE10742690A 2009-08-10 2010-08-09 Treatment of brain metastases with a combination of endothelin receptor inhibitors and cytotoxic chemotherapeutic agents HUE026005T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23268709P 2009-08-10 2009-08-10

Publications (1)

Publication Number Publication Date
HUE026005T2 true HUE026005T2 (en) 2016-04-28

Family

ID=42938154

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10742690A HUE026005T2 (en) 2009-08-10 2010-08-09 Treatment of brain metastases with a combination of endothelin receptor inhibitors and cytotoxic chemotherapeutic agents

Country Status (27)

Country Link
US (2) US8999934B2 (enEXAMPLES)
EP (1) EP2464218B1 (enEXAMPLES)
JP (1) JP2013501791A (enEXAMPLES)
KR (1) KR20120088665A (enEXAMPLES)
CN (1) CN102510719B (enEXAMPLES)
AU (1) AU2010282744B2 (enEXAMPLES)
BR (1) BR112012003103A2 (enEXAMPLES)
CA (1) CA2770397A1 (enEXAMPLES)
CL (1) CL2012000333A1 (enEXAMPLES)
DK (1) DK2464218T3 (enEXAMPLES)
EA (1) EA023864B1 (enEXAMPLES)
ES (1) ES2543280T3 (enEXAMPLES)
HR (1) HRP20150890T1 (enEXAMPLES)
HU (1) HUE026005T2 (enEXAMPLES)
IL (1) IL217915A0 (enEXAMPLES)
IN (1) IN2012DN01261A (enEXAMPLES)
MA (1) MA33571B1 (enEXAMPLES)
MX (1) MX2012001562A (enEXAMPLES)
NZ (1) NZ598078A (enEXAMPLES)
PL (1) PL2464218T3 (enEXAMPLES)
PT (1) PT2464218E (enEXAMPLES)
SG (1) SG178828A1 (enEXAMPLES)
SI (1) SI2464218T1 (enEXAMPLES)
TN (1) TN2012000054A1 (enEXAMPLES)
TW (1) TWI483938B (enEXAMPLES)
WO (1) WO2011019630A2 (enEXAMPLES)
ZA (1) ZA201200980B (enEXAMPLES)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192600A1 (en) * 2011-02-04 2013-09-30 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
MY190034A (en) 2015-03-06 2022-03-22 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CN107530340B (zh) * 2015-03-06 2021-06-08 大连万春布林医药有限公司 治疗脑肿瘤的方法
PE20180528A1 (es) 2015-07-13 2018-03-19 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
WO2017024032A2 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
JP6996728B2 (ja) * 2016-01-07 2022-01-17 学校法人自治医科大学 グルコーストランスポーター1発現用アデノ随伴ウイルスベクター
CA3013467A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
SG11201907023UA (en) 2017-02-01 2019-08-27 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
CN110799201A (zh) 2017-02-15 2020-02-14 加利福尼亚大学董事会 用于使nk细胞活化的组合物和方法
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN109232546B (zh) 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
CN118480033A (zh) 2019-05-22 2024-08-13 无锡智康弘义生物科技有限公司 一种嘧啶磺酰胺类化合物的晶型及其制备方法
CN112062857B (zh) * 2019-06-10 2024-08-09 鸿运华宁(杭州)生物医药有限公司 Eta抗体与bnp的融合蛋白质,及其药物组合物和应用
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1345920E (pt) 2000-12-18 2006-08-31 Actelion Pharmaceuticals Ltd Novas sulfonamidas e sua utilizacao como antagonistas dos receptores de endotelina
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1928409B1 (en) 2005-09-12 2012-09-12 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AU2009215329B2 (en) 2008-02-20 2014-08-21 Actelion Pharmaceuticals Ltd Combination comprising paclitaxel for treating ovarian cancer
SG192600A1 (en) 2011-02-04 2013-09-30 Actelion Pharmaceuticals Ltd Combinations comprising macitentan for the treatment of glioblastoma multiforme

Also Published As

Publication number Publication date
ES2543280T3 (es) 2015-08-17
IL217915A0 (en) 2012-03-29
EA201270264A1 (ru) 2013-02-28
AU2010282744A1 (en) 2012-03-22
TWI483938B (zh) 2015-05-11
US8999934B2 (en) 2015-04-07
HRP20150890T1 (hr) 2015-09-25
CA2770397A1 (en) 2011-02-17
US20150352113A1 (en) 2015-12-10
IN2012DN01261A (enEXAMPLES) 2015-05-15
JP2013501791A (ja) 2013-01-17
WO2011019630A2 (en) 2011-02-17
CN102510719A (zh) 2012-06-20
MX2012001562A (es) 2013-01-29
WO2011019630A3 (en) 2011-06-03
NZ598078A (en) 2013-07-26
PT2464218E (pt) 2015-09-16
SI2464218T1 (sl) 2015-10-30
MA33571B1 (fr) 2012-09-01
EP2464218B1 (en) 2015-05-27
EP2464218A2 (en) 2012-06-20
ZA201200980B (en) 2012-10-31
CL2012000333A1 (es) 2013-01-25
AU2010282744B2 (en) 2014-08-28
PL2464218T3 (pl) 2015-12-31
CN102510719B (zh) 2015-07-22
SG178828A1 (en) 2012-04-27
EA023864B1 (ru) 2016-07-29
BR112012003103A2 (pt) 2016-04-19
US20120144510A1 (en) 2012-06-07
TN2012000054A1 (en) 2013-09-19
DK2464218T3 (en) 2015-07-20
HK1171336A1 (en) 2013-03-28
TW201109315A (en) 2011-03-16
KR20120088665A (ko) 2012-08-08

Similar Documents

Publication Publication Date Title
EP2464218B1 (en) Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
Zagzag et al. Hypoxia-and vascular endothelial growth factor-induced stromal cell-derived factor-1α/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures
ES2632212T3 (es) miR-135 y composiciones que lo comprenden para el tratamiento de afecciones médicas asociadas con la serotonina
EP3106168A2 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
US20100105574A1 (en) Cancer stem cells and uses thereof
WO2009012357A2 (en) Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
CN109420170A (zh) 新型的肿瘤微环境相关靶点tak1及其在抑制肿瘤中的应用
CN101778637B (zh) 检测和调节肿瘤细胞对抗有丝分裂剂的敏感性的方法
Ma et al. Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia
JP2000504670A (ja) 腫瘍細胞の成長を抑制する方法
Bozzi et al. High CD133 expression levels in gastrointestinal stromal tumors
US9745578B2 (en) Targeting microRNA miR-409-3P to treat prostate cancer
WO2016094697A2 (en) Targeting breast cancer therapy based on stromal subtypes and cd146 composition
HK1171336B (en) Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
US20080153167A1 (en) In vivo amplification of neural progenitor cells
Haber et al. NR4A1 suppresses cancer replication stress through R-loop-dependent inhibition of immediate early gene transcriptional elongation
Han et al. A tetrahedral DNA nanoplatform with ultrasound-triggered biomimetic nanocarriers for targeted siMCM2 delivery and reversal of imatinib resistance in gastrointestinal stromal tumors
EP3269732A1 (en) Therapeutic medium for the treatment of cancer
Zickgraf SPDEF is a mediator of tumorigenicity in SSEA1-tumor-initiating cells in high grade serous ovarian cancer
CN120285196A (zh) Smad1棕榈酰化调节剂在制备增强高级别浆液性卵巢癌顺铂敏感性药物中的用途
Claes Anti-angiogenic therapy in orthotopic human glioma mofdels in nude mice. Vessel normalization impairs radiological detection and chemotherapy delivery in high-grade, diffuse gliomas
Cui Identification of inhibitors and surface markers of breast cancer stem cells
Zillhardt Stromal-mediated activation of c-MET in ovarian cancer metastasis: Opportunities for therapy
Tao et al. Niche Stiffness Sustains Bladder Cancer Stemness Via Nuclear Skeleton System